Loading
Medi1TMS / Medi2TMS / Depression · Interventional Study
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed but unpublished registry record of a small interventional study testing a novel rTMS protocol (rTMS paired with meditation-based cognitive state) in 52 participants with depression. No results are posted in this registry record, so efficacy, safety, or any clinical benefit cannot be assessed. The study remains in preliminary stage pending publication of outcomes.
Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Depression; age from 18 Years. Intervention: Medi1TMS. Compared with: Medi2TMS — Active Comparator. n = 52. 2 sites: United States.
This is a completed but unpublished registry record of a small interventional study testing a novel rTMS protocol (rTMS paired with meditation-based cognitive state) in 52 participants with depression. No results are posted in this registry record, so efficacy, safety, or any clinical benefit cannot be assessed. The study remains in preliminary stage pending publication of outcomes.
No results are posted in this registry record; efficacy and safety data are not available.
The source did not state who this applies to in practice.
This is a completed registry record with no posted results; it describes a small interventional study testing a novel rTMS protocol variant, but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04586699). This is a study registration, not published results. Lead sponsor: University of California, San Diego. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 52 participants (ACTUAL). Conditions: Depression. Interventions: DEVICE: Medi1TMS; DEVICE: Medi2TMS. Primary outcome measures: Change From Baseline Clinical Depression (Remission) , up to 6 weeks; Change From Baseline Brain Activity in Attention-to-breath Task , up to 6 weeks. Brief summary: Repetitive Transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. The ultimate goal of this treatment is to increase excitability and long-term plasticity in DLPFC, a brain region shown to be hypo-active in depression. Unfortunately, rTMS only has low to moderate efficacy; remission rates for patients range from \~15-30% in large randomized controlled trials. The focus of this research is to develop a next-generation rTMS protocol that is guided by the basic principles underlying brain plasticity, in order to improve the efficacy of rTMS for the treatment of depression. Specifically, in this study the investigators will test rTMS paired with a depression-relevant cognitive state of internal attention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.